- Home
- AYRO vs SYRS Comparison
AYRO vs SYRS Comparison
Compare AYRO & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYRO
- SYRS
- Stock Information
- Founded
- AYRO 2017
- SYRS 2011
- Country
- AYRO United States
- SYRS United States
- Employees
- AYRO N/A
- SYRS N/A
- Industry
- AYRO Telecommunications Equipment
- SYRS Biotechnology: Pharmaceutical Preparations
- Sector
- AYRO Consumer Discretionary
- SYRS Health Care
- Exchange
- AYRO Nasdaq
- SYRS Nasdaq
- Market Cap
- AYRO 4.8M
- SYRS 5.7M
- IPO Year
- AYRO N/A
- SYRS 2016
- Fundamental
- Price
- AYRO $0.59
- SYRS $0.17
- Analyst Decision
- AYRO
- SYRS Hold
- Analyst Count
- AYRO 0
- SYRS 5
- Target Price
- AYRO N/A
- SYRS $3.00
- AVG Volume (30 Days)
- AYRO 223.6K
- SYRS 1.2M
- Earning Date
- AYRO 03-31-2025
- SYRS 03-26-2025
- Dividend Yield
- AYRO N/A
- SYRS N/A
- EPS Growth
- AYRO N/A
- SYRS N/A
- EPS
- AYRO N/A
- SYRS N/A
- Revenue
- AYRO $221,671.00
- SYRS $386,000.00
- Revenue This Year
- AYRO $2,424.87
- SYRS N/A
- Revenue Next Year
- AYRO N/A
- SYRS N/A
- P/E Ratio
- AYRO N/A
- SYRS N/A
- Revenue Growth
- AYRO N/A
- SYRS N/A
- 52 Week Low
- AYRO $0.49
- SYRS $0.16
- 52 Week High
- AYRO $1.83
- SYRS $7.96
- Technical
- Relative Strength Index (RSI)
- AYRO 39.78
- SYRS 38.78
- Support Level
- AYRO $0.49
- SYRS $0.16
- Resistance Level
- AYRO $0.85
- SYRS $0.20
- Average True Range (ATR)
- AYRO 0.06
- SYRS 0.02
- MACD
- AYRO -0.00
- SYRS 0.01
- Stochastic Oscillator
- AYRO 28.33
- SYRS 35.75
About AYRO AYRO Inc.
AYRO Inc design and manufacture compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, which is the design, development, manufacturing, and sales of electric vehicles, and operates in the United States.
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.